Business
ANI Pharmaceuticals Announces Launch of Ranitidine Capsules
BAUDETTE, Minn., June 25, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Ranitidine Capsules, 150mg and
About this update from Ani Pharmaceuticals, Inc.
[{"type":"text","content":"BAUDETTE, Minn., June 25, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (\"ANI\") (Nasdaq: ANIP) today announced the launch of Ranitidine Capsules, 150mg and 300mg. The current annual U.S. market for this product is approximately $40 million, according to Iqvia/IMS Health.\nArthur S. Przybyl, ANI's President and CEO stated, \"This launch brings our generic portfolio to 34 commercial products and represents our third generic product introduction in 2019. We are excited to commercialize the first product from our partnership with Appco Pharma LLC, which we entered into in March 2018, and we look forward to additional future launches through this partnership as we advance our collaboration.\"\nAbout Ranitidine Capsules\nRanitidine Hydrochloride is an oral histamine H2-receptor antagonist with multiple indications. Ranitidine Capsules are indicated in: the short-term treatment of active duodenal, maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers, the treatment of pathological hypersecretory conditions, short-term treatment of active, benign gastric ulcer, maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers, treatment of GERD, treatment of endoscopically diagnosed erosive esophagitis, and maintenance of healing of erosive esophagitis. \nFor more information, including the complete list of indications and usages, please see the Full Prescribing Information.\nAbout ANI\nANI Pharmaceuticals, Inc. (the \"Company\" or \"ANI\") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com.\nForward-Looking Statements \nTo the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company's future operations, products financial position, operating results and prospect...